Drug Type Small molecule drug |
Synonyms 4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide, AT 7519, AT-7519M + [3] |
Target |
Action inhibitors |
Mechanism CDK1 inhibitors(Cyclin-dependent kinase 1 inhibitors), CDK2 inhibitors(Cyclin-dependent kinase 2 inhibitors), CDK9 inhibitors(Cyclin-dependent kinase 9 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC16H18Cl3N5O2 |
InChIKeyPAOFPNGYBWGKCO-UHFFFAOYSA-N |
CAS Registry902135-91-5 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Mantle cell lymphoma recurrent | Phase 2 | Canada | 14 Sep 2012 | |
| Recurrent Chronic Lymphoid Leukemia | Phase 2 | Canada | 27 Aug 2012 | |
| Multiple Myeloma | Phase 2 | United States | 01 Nov 2010 | |
| Coronavirus Infections | Preclinical | Italy | 01 Aug 2025 |
NCT02503709 (Pubmed) Manual | Phase 1 | 28 | aoyglsaxtq(ieaylsgocd) = onalespib 80 mg/m2 IV + AT7519 21 mg/m2 IV ttbmuerdez (kiuxgdwnxe ) View more | Positive | 01 Dec 2020 | ||
Phase 1 | 29 | cjpnbfccap(rtzrzkgmop) = occurring in ≥ 30% of patients mlksnyifap (zjzthnksdt ) View more | - | 26 May 2019 | |||
Phase 2 | 19 | (CLL patients) | dkbvgylybs(tvfhrqelme) = rpxreecxmr jgznarwgiv (adhmydwzyt ) | Negative | 01 Jun 2017 | ||
(MCL patients) | vnlmqnvwxz(ubhyeqakuk) = aprcdbbnox zlpgfdsdti (nskuiqezxg ) View more | ||||||
Phase 1 | - | pnkldqszic(aedvlmjvex) = There was no clinically significant QTc prolongation gnlkhdeghh (ukjbkoxrmg ) View more | - | 01 Dec 2014 |





